Could a drug combo tame deadly pancreatic cancer?
NCT ID NCT06953999
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This large Phase 3 trial tests whether adding two immune-boosting drugs (ivonescimab and AK117) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 participants will be randomly assigned to get the new drugs or a placebo, all with chemo. The goal is to see if the combination improves survival and slows cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab and AK117 (immune-boosting drugs) plus chemotherapy (albumin-bound paclitaxel and gemcitabine)
What this could lead to
If it works, this could offer a new first-line treatment option that helps people with metastatic pancreatic cancer live longer.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. The drugs may cause side effects like immune reactions or infections, and the benefit over standard chemotherapy is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 20032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••